Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Genitourinary 2CNS 2Gastrointestinal 1Endocrine 1

Conditions

Osteosarcoma 9Sarcoma 8Sarcoma, Ewing 7Wilms Tumor 2Rhabdomyosarcoma 2Histiocytoma, Malignant Fibrous 2Carcinoma, Renal Cell 2Carcinoma, Medullary 2Carcinoma, Hepatocellular 2Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Kaposi 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Rhabdoid Tumor 1Recurrence 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neuroblastoma 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Leiomyosarcoma 1Hepatoblastoma 1HIV Infections 1Gliosarcoma 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Endometrial Neoplasms 1Central Nervous System Neoplasms 1

Interventions

Vincristine 25Cyclophosphamide 25Irinotecan 21Temozolomide 18Doxorubicin 16Radiotherapy 15Filgrastim 15Ifosfamide 14Dactinomycin 14Etoposide 11Vinorelbine 9Melphalan 9Magnetic Resonance Spectroscopy 9Granulocyte Colony-Stimulating Factor 9Radiation 8pegfilgrastim 7X-Rays 7Specimen Handling 7Sirolimus 7Topotecan 6Phantoms, Imaging 6Peripheral Blood Stem Cell Transplantation 6Gemcitabine 6cixutumumab 5Busulfan 5Biopsy 5temsirolimus 4irinotecan sucrosofate 4fludarabine 4etoposide phosphate 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Rhabdomyosarcoma × cabozantinib × Sarcoma × Clear all
NCT02867592 2026-05-27

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
109 enrolled 24 charts
CNSEndocrineGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Wilms Tumor, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Central Nervous System Neoplasms, Hepatoblastoma, Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part, Adrenocortical Carcinoma, Carcinoma, Medullary

NCT05135975 2025-08-12

A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

Nationwide Children's Hospital

Phase 2 Recruiting
86 enrolled
CNSGenitourinarySarcoma

Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡